Although the precise mechanism underlying the discrepancy between the two studies has yet to be determined, our finding provides a basis for further exploring the use of AMD3100 to prevent and/or treat TID and possibly other autoimmune diseases in patients with elevated CXCL12 or CXCR4 expression. This evidence concerns the gene CXCL12 and autoimmune disease.